
Axcella Health AXLA
Quarterly report 2023-Q2
added 08-03-2023
Axcella Health Shares 2011-2026 | AXLA
Annual Shares Axcella Health
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 54.4 M | 38.1 M | 36.9 M | 16.6 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 54.4 M | 16.6 M | 36.5 M |
Quarterly Shares Axcella Health
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 73.7 M | 73.7 M | 73.7 M | 52.6 M | 52.6 M | 41.4 M | 39.2 M | 38.2 M | 37.7 M | 37.7 M | 37.6 M | 36.9 M | 29.2 M | 23.2 M | 23.2 M | 23.1 M | 15.2 M | 4.78 M | 4.77 M | 4.77 M | 4.41 M | 4.23 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 73.7 M | 4.23 M | 33.3 M |
Shares of other stocks in the Biotechnology industry
| Issuer | Shares | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
33.4 M | - | 2.43 % | $ 254 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
46.7 M | $ 21.94 | 2.48 % | $ 1.03 B | ||
|
I-Mab
IMAB
|
220 M | - | - | $ 866 M | ||
|
Aeglea BioTherapeutics
AGLE
|
78.2 M | - | - | $ 1.01 B | ||
|
Midatech Pharma plc
MTP
|
80.5 M | - | -18.52 % | $ 27.3 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
219 M | - | - | $ 40.3 B | ||
|
Aptorum Group Limited
APM
|
7.35 M | $ 0.9 | 0.49 % | $ 6.62 M | ||
|
Biophytis SA
BPTS
|
118 M | - | -13.47 % | $ 169 M | ||
|
Genfit SA
GNFT
|
44.7 B | - | 2.54 % | $ 160 B | ||
|
ACADIA Pharmaceuticals
ACAD
|
166 M | $ 22.66 | 3.19 % | $ 3.76 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.58 M | - | -1.52 % | $ 24.7 M | ||
|
Advaxis
ADXS
|
6.02 M | - | -9.65 % | $ 45.9 M | ||
|
AIkido Pharma
AIKI
|
14.3 M | - | 1.93 % | $ 17.4 M | ||
|
Akouos
AKUS
|
34.4 M | - | 0.23 % | $ 488 M | ||
|
Allakos
ALLK
|
86.8 M | - | - | $ 28.6 M | ||
|
AlloVir
ALVR
|
15.3 M | - | 4.14 % | $ 49.1 M | ||
|
Ampio Pharmaceuticals
AMPE
|
810 K | - | -11.43 % | $ 502 K | ||
|
Институт стволовых клеток человека
ISKJ
|
75 M | - | - | - | ||
|
Applied Molecular Transport
AMTI
|
38.8 M | - | - | $ 10.1 M | ||
|
Aeterna Zentaris
AEZS
|
115 M | - | 5.93 % | $ 314 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
9.27 M | - | -2.5 % | $ 5.88 M | ||
|
Applied Therapeutics
APLT
|
84.2 M | - | - | $ 8.42 M | ||
|
Aptinyx
APTX
|
67.7 M | - | -39.0 % | $ 4.57 M | ||
|
AgeX Therapeutics
AGE
|
10.2 M | - | -10.17 % | $ 12.2 K | ||
|
Aravive
ARAV
|
36.4 M | - | -13.39 % | $ 1.45 M | ||
|
Aridis Pharmaceuticals
ARDS
|
18.8 M | - | 17.91 % | $ 11.1 M | ||
|
BioNTech SE
BNTX
|
244 M | $ 102.75 | -2.57 % | $ 27.2 B | ||
|
Avenue Therapeutics
ATXI
|
3.13 M | - | -52.27 % | $ 4.45 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
45 M | - | - | $ 26.5 M | ||
|
Aquestive Therapeutics
AQST
|
107 M | $ 4.14 | 1.35 % | $ 443 M | ||
|
Arcutis Biotherapeutics
ARQT
|
127 M | $ 23.58 | 1.38 % | $ 3 B | ||
|
Ayala Pharmaceuticals
AYLA
|
15.4 M | - | - | $ 7.46 M | ||
|
Autolus Therapeutics plc
AUTL
|
266 M | $ 1.44 | -0.35 % | $ 383 M | ||
|
Aptose Biosciences
APTO
|
2.45 M | - | -45.71 % | $ 1.2 M | ||
|
AstraZeneca PLC
AZN
|
1.42 B | - | - | $ 96.9 B | ||
|
AVROBIO
AVRO
|
44.3 M | - | 1083.1 % | $ 745 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
1.65 M | $ 2.92 | -0.45 % | $ 4.81 M | ||
|
BioDelivery Sciences International
BDSI
|
99.3 M | - | -4.8 % | $ 255 M | ||
|
BeiGene, Ltd.
BGNE
|
1.42 B | - | 0.49 % | $ 251 B | ||
|
Akero Therapeutics
AKRO
|
67.1 M | - | - | $ 3.67 B | ||
|
CureVac N.V.
CVAC
|
186 M | - | - | $ 867 M | ||
|
bluebird bio
BLUE
|
110 M | - | - | $ 546 M | ||
|
ContraFect Corporation
CFRX
|
521 K | - | -5.16 % | $ 5.39 M | ||
|
Cardiff Oncology
CRDF
|
66.8 M | $ 1.72 | - | $ 115 M | ||
|
BioXcel Therapeutics
BTAI
|
12.2 M | $ 1.1 | 3.77 % | $ 13.4 M | ||
|
Cabaletta Bio
CABA
|
100 M | $ 2.99 | 1.19 % | $ 300 M | ||
|
Cara Therapeutics
CARA
|
7.42 M | - | -3.03 % | $ 260 M | ||
|
Allena Pharmaceuticals
ALNA
|
68 M | - | 3.16 % | $ 1.9 M | ||
|
CASI Pharmaceuticals
CASI
|
136 M | - | - | $ 35.4 M | ||
|
CymaBay Therapeutics
CBAY
|
106 M | - | - | $ 3.45 B |